Mesoblast Limited
NASDAQ:MESOBiotechnology
+$0.26 today
- Market cap
- $1.51B
- Beta
- 0.79
- P/E (TTM)
- -23.6
- EPS (TTM)
- -$0.06
Volume 0.13M
Average 0.21M
MESO Operating Expenses
Total costs of running the business that are not directly tied to producing goods or services sold.
Mesoblast LimitedNASDAQ: MESO
Operating Expenses · Q4 FY2026 · quarter ended Jun 2026
Operating expenses growth accelerates
Q4 FY2026 operating expenses of $40.08M rose 120.9% year over year, ahead of the +108.9% change in trailing-twelve-month operating expenses. Sequentially, it rose 0.0% from the prior quarter. Over 3 fiscal years it compounded at +25.9% a year.
Context
- Operating expenses amounted to 126.7% of revenue in FY2026, down 306.5 pp from a year earlier.
- Operating expenses increased in 2 of the last 3 fiscal years.
- FY2026 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +120.9% holds above the trailing-twelve-month pace of +108.9%.
Sources:Income StatementText generated from reported figures; not investment advice.
Operating Expenses history
USD · from the income statement
- Latest · FY2026
- 153.08M USD
- Year-over-year change
- +105.4%
- 4-year CAGR
- +14.0%
| Period | Period end | Operating Expenses | YoY change |
|---|---|---|---|
| FY2026 | 2026-06-30 | 153.08M | +105.4% |
| FY2025 | 2025-06-30 | 74.51M | +52.1% |
| FY2024 | 2024-06-30 | 48.98M | -36.2% |
| FY2023 | 2023-06-30 | 76.79M | -15.4% |
| FY2022 | 2022-06-30 | 90.79M | — |
Operating Expenses vs competitors
How MESO compares with its peers on the latest reported figures
- MESO's LTM Jun 2026 operating expenses of $154.86M is the 2nd highest of the 6 companies compared; the peer median is $81.5M.
- Its year-over-year change of +108.9% is the 2nd highest of 6, against a peer median of +5.0%.
- Operating expenses amounts to 128.8% of revenue for MESO, versus a peer median of 330.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $740.02M | -0.1% | +14.3% | 54.5% | |
| LTM Jun 2026 | $154.86M | +108.9% | +25.9% | 128.8% | |
| LTM Mar 2026 | $113.16M | -11.7% | -28.7% | 1791.7% | |
| LTM Dec 2025 | $81.5M | +5.0% | +50.5% | 307.0% | |
| LTM Mar 2026 | $77.53M | +359.8% | +118.0% | — | |
| LTM Mar 2026 | $52.19M | +70.5% | -0.9% | 353.1% | |
| Peer median (excluding MESO) | $81.5M | +5.0% | +14.3% | 330.0% | |
Competitors are the stored peer set for MESO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2022 Jun 2022 | FY2023 Jun 2023 | FY2024 Jun 2024 | FY2025 Jun 2025 | FY2026 Jun 2026 |
|---|---|---|---|---|---|
| Revenue | 10.21M | 7.5M | 5.9M | 17.2M | 120.79M |
| Cost of Revenue | 63.57M | 54.92M | 41.07M | 5.13M | 19.21M |
| Gross Profit | (53.36M) | (47.42M) | (35.17M) | 12.07M | 101.58M |
| Gross Margin | -522.6% | -632.2% | -595.9% | 70.2% | 84.1% |
| Research & Development | 32.82M | 27.19M | 25.35M | 34.81M | 97.94M |
| Selling, General & Admin | 57.97M | 53.11M | 23.63M | 39.31M | 55.13M |
| Operating Expenses | 90.79M | 76.79M | 48.98M | 74.51M | 153.08M |
| Depreciation & Amortization | 4.38M | 4.11M | 1.9M | 6.4M | 8.62M |
| EBITDA | (76.57M) | (58.55M) | (56.08M) | (73.66M) | (42.88M) |
| EBITDA Margin | -749.9% | -780.6% | -950.1% | -428.3% | -35.5% |
| Operating Income | (80.57M) | (69.29M) | (84.15M) | (62.44M) | (51.5M) |
| Operating Margin | -789.1% | -923.7% | -1425.7% | -363.1% | -42.6% |
| Interest Income | 0 | 831K | 1.82M | 3.55M | 3.93M |
| Interest Expense | 17.29M | 19.44M | 20.66M | 22.93M | 23.95M |
| Other Income / Expenses | (10.48M) | (12.81M) | (4M) | (39.37M) | (5.64M) |
| Income Before Tax | (91.59M) | (82.1M) | (88.15M) | (101.81M) | (57.14M) |
| Pre-Tax Margin | -896.9% | -1094.5% | -1493.5% | -592.0% | -47.3% |
| Income Tax Expense | (239K) | (212K) | (191K) | 330K | 615.74K |
| Net Income | (91.35M) | (81.89M) | (87.96M) | (102.14M) | (57.76M) |
| Net Margin | -894.6% | -1091.7% | -1490.3% | -593.9% | -47.8% |
| EPS (Basic) | (1.30) | (0.98) | (0.89) | (0.84) | (0.45) |
| EPS (Diluted) | (1.30) | (0.98) | (0.89) | (0.84) | (0.45) |
| Weighted Avg Shares | 68.27M | 83.77M | 98.67M | 120.78M | 129.49M |
| Weighted Avg Shares (Diluted) | 68.29M | 83.93M | 98.67M | 120.78M | 129.49M |
Mesoblast Limited
NASDAQ:MESO
Intrinsic Alpha fair value
Locked
Current Price
$11.64
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.